Travis Steed
BofA Securities, Research Division

We have Payman Khales.

Payman Khales
CEO, President & Director

Khales.

Travis Steed
BofA Securities, Research Division

Khales, President and CEO; and Diron Smith, Executive VP and CFO.

Travis Steed
BofA Securities, Research Division

So maybe just to start out, one question that I get a lot, and I don't have a good answer on is, like, trends on in-sourcing from some of the bigger medtech strategics. Is this a trend that's increasing? Or how are strategics thinking about in-sourcing versus outsourcing some of the manufacturing?

Payman Khales
CEO, President & Director

Sure. And thanks for having us, Travis. And you got most of the letters right in Integer. So yes, it's good to be here.

Travis Steed
BofA Securities, Research Division

Apologies.

Payman Khales
CEO, President & Director

Yes, no worries at all. So if you really think about what our customers are focused on, the OEMs, their primary focus is to bring, develop and bring to market the next generation of therapies. They need companies like us to help them with that design development in terms of the manufacturability, in terms of making sure that they are putting their efforts and focus where they can generate the most value, which is getting with physicians, trying to mature the therapies, trying to get over the regulatory hurdles.

We don't really see a trend towards in-sourcing. In fact, we see the trends that are more positively towards outsourcing because that companies like us with the scale and breadth of capabilities that we